Retinal Edema Clinical Trial
— ResistantOfficial title:
Resistant Diabetic Macular Edema and Suprachoroidal Injection
Prospective interventional study on 60 eyes of resistant diabetic macular edema and central retinal vein occlusion that will receive suprachoroidal injection of Triamcinolone Acetonide (SCTA).
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | February 1, 2025 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients fulfilling one or more of the following criteria will be considered to have resistant DME after at least 3 consecutive monthly anti VEGF injections in the previous 6 months: - Central macular thickness greater than 300 µm by spectral-domain optical coherence tomography (SD-OCT). - Reduction of retinal thickness by less than 10% of baseline retinal thickness. - Suboptimal visual improvement (failure to gain at least 3 lines on the Snellen chart) and patients with recent onset central retinal vein occlusion less than 3 months. Exclusion Criteria: - Previous intraocular surgery (except cataract surgery done more than 6 months before the study). - Coincident retinal pathology as choroidal neovascular membrane and age related macular degeneration. - Previous laser photocoagulation. - Intravitreal injection of triamcinolone acetonide. - Prior ocular inflammation. - The presence of retinal degeneration. - Patients who didnot complete 6 months of follow up |
Country | Name | City | State |
---|---|---|---|
Egypt | Tanta University | Tanta | El Gharbia |
Lead Sponsor | Collaborator |
---|---|
Tanta University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement of central macular thickness | Reduction of the central macular thickness below 300 um | 1 month | |
Secondary | improved vision | Improvement of best corrected visual acuity | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05130385 -
High Resolution Optical Coherence Tomography
|
||
Completed |
NCT01273727 -
Ozurdex for Macular Edema Post Membrane Peeling
|
Phase 2/Phase 3 | |
Recruiting |
NCT04501367 -
Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.
|
Phase 4 | |
Completed |
NCT01847638 -
Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
|
N/A |